Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
6.72
-0.08 (-1.18%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Longeveron Revenue
Longeveron had revenue of $287.00K in the quarter ending June 30, 2026, a decrease of -9.18%. This brings the company's revenue in the last twelve months to $1.19M, down -42.74% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%.
Revenue (ttm)
$1.19M
Revenue Growth
-42.74%
P/S Ratio
18.05
Revenue / Employee
$31,237
Employees
38
Market Cap
21.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Marker Therapeutics | 3.55M |
| ABVC BioPharma | 797.92K |
| Allarity Therapeutics | 345.00K |
| Cocrystal Pharma | 330.00K |
| Neuphoria Therapeutics | -13.27K |
LGVN News
- 4 days ago - Longeveron Inc trading halted, news pending - TheFly
- 6 days ago - Longeveron announces 1-for-10 reverse stock split - TheFly
- 6 days ago - Longeveron Announces 1-for-10 Reverse Stock Split - GlobeNewsWire
- 11 days ago - Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed - TheFly
- 11 days ago - Longeveron Appoints Nirav Jhaveri as Chief Financial Officer - GlobeNewsWire
- 13 days ago - Longeveron reports Q2 EPS (19c) vs. (33c) last year - TheFly
- 18 days ago - Longeveron Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Longeveron Quarterly report: Q2 2026 - Filings